HC
QNCX icon

Hurley Capital’s Quince Therapeutics QNCX Stock Holding History

Hurley Capital’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$12 – 714
2026
Q1 		$12 Hold
1
– – ﹤0.01% 663
2025
Q4 		$405 Hold
1
– – ﹤0.01% 550
2025
Q3 		$197 Hold
1
– – ﹤0.01% 656
2025
Q2 		$200 Hold
1
– – ﹤0.01% 441
2025
Q1 		$161 Hold
1
– – ﹤0.01% 479
2024
Q4 		$236 Buy
+1
New +$300 ﹤0.01% 386

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Hurley Capital's QNCX Position: Q2 2026 in Review

Hurley Capital sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 1 share — an estimated $12 sold.

Hurley Capital first reported a position in QNCX in Q4 2024 and held it in 6 quarters. The position peaked at $405 in Q4 2025. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Hurley Capital reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hurley Capital sold 1 Quince Therapeutics share in Q2 2026, an estimated $12.
  • Hurley Capital first reported a position in Quince Therapeutics in Q4 2024 and held it in 6 quarters.
  • Hurley Capital's Quince Therapeutics position peaked at $405 in Q4 2025.
  • 26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.